- Previous Close
1.7500 - Open
1.7300 - Bid 1.6700 x 2400
- Ask 1.7000 x 2400
- Day's Range
1.6750 - 1.7400 - 52 Week Range
0.7000 - 3.4000 - Volume
3,369,430 - Avg. Volume
5,595,403 - Market Cap (intraday)
329.658M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8500 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.59
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
www.esperion.com240
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ESPR
View More
Performance Overview: ESPR
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ESPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ESPR
View MoreValuation Measures
Market Cap
330.64M
Enterprise Value
410.47M
Trailing P/E
--
Forward P/E
1.31
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.88
Price/Book (mrq)
--
Enterprise Value/Revenue
1.48
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.46%
Return on Assets (ttm)
1.05%
Return on Equity (ttm)
--
Revenue (ttm)
277.79M
Net Income Avi to Common (ttm)
-98.5M
Diluted EPS (ttm)
-0.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
189.3M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
6.91M
Research Analysis: ESPR
View MoreCompany Insights: ESPR
ESPR does not have Company Insights
Research Reports: ESPR
View MoreDaily – Vickers Top Buyers & Sellers for 05/27/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/24/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/10/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.